Clinical Trial Calendar

Results Date
Company Name
Q2 2021
Entera Bio Ltd.
Final Biomarker Data from 2.5 mg Dose in Phase 2 Study of EB613
Q2 2021
Corbus Pharmaceuticals Holdings, Inc.
Topline data from Phase 3 study of Lenabasum (DETERMINE)
Dermatomyositis (DM)
Q2 2021
Novan Inc.
Top-line efficacy results from phase 3 trial of SB206 (B-SIMPLE4)
Q2 2021
AzurRx BioPharma, Inc.
Topline data from phase 2 combination therapy trial of MS1819 with PERT therapy
Cystic fibrosis (CF) and chronic pancreatitis (CP) patients with exocrine pancreatic insufficiency (EPI)
Q2 2021
Celldex Therapeutics Inc.
Full results from Phase 1b study of CDX-0159
Chronic spontaneous urticaria (CSU)
Q2 2021
Frequency therapeutics
Top-line data from Phase 2a clinical trial of FX-322
Sensorineural hearing loss or SNHL
Q2 2021
Top-line data from phase IIa clinical trial of ABX464 (ABX464-301)
Moderate to severe active rheumatoid arthritis
Clene Inc.
Updated blinded interim data from phase II study of CNM-Au8 (VISIONARY-MS)
Stable relapsing multiple sclerosis (MS) who have chronic optic neuropathy
Clene Inc.
Updated interim data from phase II study of CNM-Au8 (REPAIR-MS)
Multiple Sclerosis
Cyclo Therapeutics, Inc.
Update on safety and efficacy results for Phase I/II trial of hydroxypropyl beta-cyclodextrin (HPBCD) administered intravenously in patients with Niemann-Pick disease type C1
Niemann-Pick disease type C1
Feb 2021
Completion of phase Ib trial of NEO-PV-01 and Keytruda
Advanced or metastatic nonsquamous non-small cell lung carcinoma
Late Feb 2021
Otonomy Inc.
Results from Phase 3 trial of OTIVIDEX
Ménière’s disease
Arcus Biosciences, Inc
Updated data from phase I portion of phase I/Ib study of AB680 in combination with Zimberelimab and nab-paclitaxel plus gemcitabine
Front-line metastatic pancreatic cancer
Q1 2021
Updates from phase IIa open label extension trial of IMR-687
Sickle cell disease
Q1 2021
Lineage Cell Therapeutics, Inc.
New and accumulated data from Phase 1/2a trial of OpRegen
Dry age-related macular degeneration with geographic atrophy
AlloVir, Inc.
Initial data from phase II placebo-controlled study to assess safety and efficacy of Viralym-M compared to placebo
BKV, cytomegalovirus, or CMV, adenovirus, or AdV, Epstein-Barr virus, or EBV, and human herpesvirus 6, or HHV-6 and JCV infection and/or disease, in high-risk patients after allogeneic hematopoietic cell transplant
after Q1 2021
SELLAS Life Sciences Group, Inc.
Updated data from phase I/II trial of Galinpepimut-S (GPS) in combination with Keytruda i
Advanced Wilms Tumor 1 positive (WT1+) cancers
after Q1 2021
SELLAS Life Sciences Group, Inc.
Updated data from phase I trial of Galinpepimut-S in combination with Opdivo
Patients with macroscopic measurable deposits of malignant pleural mesothelioma
after Q1 2021
Topline data from phase I trial evaluating the safety, tolerability, and pharmacokinetics (PK) of ANAVEX3-71
PK in healthy volunteers
Q1 2021
Idera Pharmaceuticals, Inc.
Topline data from phase 3 trial of tilsotolimod in combination with ipilimumab versus ipilimumab (ILLUMINATE-301)
Anti-PD-1 Refractory Advanced Melanoma
InflaRx N.V.
Results from phase IIa open label trial of IFX-1
Pyoderma Gangraenosum (PG)
Q1 2021
CTI BioPharma Corp.
Completion of NDA submission of Pacritinib
Myelofibrosis patients with severe thrombocytopenia.
Late Q1 2021
Brainstorm Cell Therapeutics Inc.
Top-line data from phase II trial of NurOwn
Progressive multiple sclerosis in adults
BridgeBio Pharma, Inc.
Initial data from Phase 2 dose ranging study of Low-dose infigratinib – FGFR1-3 inhibitor
after Q1 2021
Oncternal Therapeutics Inc.
Clinical data update from phase Ib study of Cirmtuzumab
HER2-negative breast cancer